New hope for failing kidneys? drug trial targets most severe cases
NCT ID NCT07074418
Summary
This study is testing if a drug called empagliflozin can help protect the kidneys in people with very advanced chronic kidney disease and type 2 diabetes. It will involve about 34 participants who have severely reduced kidney function. The main goal is to see if the drug safely reduces protein in the urine, which is a sign of kidney damage, over short 6-week treatment periods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Nice - Hôpital Pasteur 2
Nice, Alpes-Maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.